Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TED-N in sub-acute spinal cord injury
NCT04812431Phase 2Recruiting
- Sponsor
- S.Biomedics
- Start
- Sep 2021
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in spinal cord injury (SCI), sponsored by S.Biomedics. Primary endpoints: Changes of occurred adverse events during the clinical study at 72 weeks, Rate of abnormal signs as assessed through physical examination at 72 weeks and 8 more. Started Sep 2021; status: recruiting.
02
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04812431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812431.